Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.
Bernstein lowered the firm’s price target on Johnson & Johnson to $160 from $177 and keeps a Market Perform rating on the shares as part of a ...
As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability ...
Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to ...
The New Brunswick, N.J., pharmaceutical giant said posdinemab has shown potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid from treated Alzheimer's patients, and in ...
Johnson & Johnson announced that the U.S. Food and Drug Administration has granted Fast Track designation to posdinemab, a phosphorylated ...
Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow ...
Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) and keeping the price ...
Without any changes to the program, the fund is set to run out of money for full payments by as early as 2035.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback